Welcome to the Sentinel Innovation and Methods Seminar Series

The webinar will begin momentarily.

Please visit www.sentinelinitiative.org for recordings of past sessions and details on upcoming webinars.

Note: closed-captioning for today's webinar will be available on the recording posted at the link above.

Opportunities and Challenges in the use of Large Language Models for Post-Marketing Surveillance of Medical Products

Michael E. Matheny, MD, MS, MPH
Director, Center for Improving the Publics' Health Through Informatics
Professor, Departments of Biomedical Informatics, Medicine, and Biostatistics
Vanderbilt University Medical Center

Associate Director for Data Analytics, VINCI
Associate Director, Advanced Fellowship in Medical Informatics
Tennessee Valley Healthcare System VA
Twitter: @MichaelEMatheny
Email: michael.Matheny@va.gov, michael.Matheny@Vanderbilt.edu, michael.Matheny@vumc.org

04/22/2024

Disclosure

- I have no conflicts of interest regarding the materials, software, or algorithms presented in this presentation.
- All funding received in the last 3 years are research grants and contracts from FDA Sentinel, VA ORD & HSR&D, NIH NHLBI & NIDDK, NIH-VA-DoD Joint funding, and a medical device public-private partnership (NESTcc [FDA U01])
- This work was supported by Task Order **75F40119F19002** under Master Agreement **75F40119D10037** from the U.S. Food and Drug Administration (FDA).
- The views expressed in this presentation represent those of the presenter and do not necessarily represent the official views of the U.S. FDA.

What is Sentinel?

Public Law 110–85
110th Congress

An Act

To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs and for medical devices, to enhance the postmarket authorities of the Food and Drug Administration with respect to the safety of drugs, and for other purposes.

Sept. 27, 2007
[H.R. 3580]

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

Food and Drug Administration Amendments Act of 2007.
21 USC 301 note.

SECTION 1. SHORT TITLE.

This Act may be cited as the "Food and Drug Administration Amendments Act of 2007".

Establishment of a post-market risk identification and analysis system

SEC. 905. ACTIVE POSTMARKET RISK IDENTIFICATION AND ANALYSIS.

(a) IN GENERAL.—Subsection (k) of section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) is amended by adding at the end the following:

"(3) ACTIVE POSTMARKET RISK IDENTIFICATION.—

"(A) DEFINITION.—In this paragraph, the term 'data' refers to information with respect to a drug approved under this section or under section 351 of the Public Health Service Act, including claims data, patient survey data, standardized analytic files that allow for the pooling and analysis of data from disparate data environments, and any other data deemed appropriate by the Secretary.

"(B) DEVELOPMENT OF POSTMARKET RISK IDENTIFICATION AND ANALYSIS METHODS.—The Secretary shall, not later than 2 years after the date of the enactment of the Food and Drug Administration Amendments Act of 2007, in collaboration with public, academic, and private entities—

"(i) develop methods to obtain access to disparate data sources including the data sources specified in subparagraph (C);

"(ii) develop validated methods for the establishment of a postmarket risk identification and analysis system to link and analyze safety data from multiple sources, with the goals of including, in aggregate—

"(I) at least 25,000,000 patients by July 1, 2010; and

"(II) at least 100,000,000 patients by July 1, 2012; and

"(iii) convene a committee of experts, including individuals who are recognized in the field of protecting data privacy and security, to make recommendations to the Secretary on the development of tools and methods for the ethical and scientific uses for, and communication of, postmarketing data specified under subparagraph (C), including recommendations on the development of effective research methods for the study of drug safety questions.

"(C) ESTABLISHMENT OF THE POSTMARKET RISK IDENTIFICATION AND ANALYSIS SYSTEM.—

"(i) IN GENERAL.—The Secretary shall, not later than 1 year after the development of the risk identification and analysis methods under subparagraph (B), establish and maintain procedures—

Slide courtesy of Rishi Desai: https://www.govinfo.gov/content/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf

FDA's Sentinel System

- 2007 FDA Amendments Act mandates FDA to establish ***active surveillance system*** for monitoring drugs using electronic healthcare data.
- Through the Sentinel Initiative, FDA aims to assess the post-marketing safety of approved medical products.



Slide courtesy of Rishi Desai

Sentinel Distributed Database (SDD)

1. Aetna, a CVS Health company
2. Carelon Research/Elevance Health
3. Duke University School of Medicine: Department of Population Health Sciences (Medicare Fee-for-Service and Medicaid data)
4. HealthPartners Institute
5. Humana, Inc.
6. Kaiser Permanente Colorado Institute for Health Research
7. Kaiser Permanente Hawai'i, Center for Integrated Health Care Research
8. Kaiser Foundation Health Plan of the Mid-Atlantic States, Inc.
9. Kaiser Permanente Northwest Center for Health Research
10. Kaiser Permanente Washington Health Research Institute
11. Marshfield Clinic Research Institute
12. Optum
13. Vanderbilt University Medical Center, Department of Health Policy (Tennessee Medicaid data)

- **463.3 million unique patient identifiers (2000-2023)***
- **112.9 million members** currently accruing new data
- **19.7 billion** pharmacy dispenses
- **20.2 billion** unique medical encounters

*Potential for double-counting if individuals moved between Data Partner (DP) health plans.

Slide courtesy of Rishi Desai

Active Risk Identification and Analysis (ARIA)



Slide courtesy of Rishi Desai

ARIA Insufficiency



[1]*A single safety concern may be insufficient for analysis in ARIA for several reasons; thus, a single safety concern may be counted in multiple epidemiologic categories.*
***ARIA:** Active Risk Identification & Analysis. **FD&C Act:** Federal Food, Drug, and Cosmetic Act.*

Maro et al. CPT. 2023 Slide courtesy of Rishi Desai

Reasons for ARIA Insufficiency

Table 4 Reasons for determinations of ARIA insufficiency

Reasons for insufficiency	Number of determinations	Example	Direction of future development
Insufficient supplemental structured clinical data	89	Lack of laboratory, imaging, or vital signs data	Addressable with the addition of EHR data elements into ARIA[35,36]
Inability of ARIA tools to perform required analysis	82	Insufficient signal identification tool	ARIA has integrated signal identification abilities (**Figure 1**)[16–18]
Study requires data elements captured in unstructured clinical data, such as clinical notes	73	Lack of radiology or pathology findings in notes	Addressable with development of feature engineering capabilities to extract and structure these data[37]
Absence of validated code algorithm	72	No gold-standard chart review was performed for outcome of interest	Sentinel has performed several gold standard chart validations[38–42] but these require substantial resources. Efforts underway to investigate rapid silver standard reviews.
Identification of clinical concepts with available code algorithms/terminologies is not possible or inadequate	60	Codes do not exist for concept or validated performance characteristics are inadequate	Potentially addressable with added EHR elements but if outcome is not well-defined or new (e.g., long COVID), there may be substantial hurdles to identification
Inadequate sample size	57	Low uptake of drug	Non-actionable as ARIA is the largest system of its kind
Requires linkage to additional data source that is unavailable	52	Inability to ascertain cause of death	Additional linkages are possible with significant financial resources
Insufficient observation time available	44	Inability to follow patients across healthcare plans or systems	Actionable with substantial further research and development and resolution of data governance issues[43]
Insufficient mother-infant linkage	24	Lack of ability to connect mothers and infants	Resolved with 2018 integration of Mother-Infant Linkage table[15]
Insufficient inpatient data	18	Inability to access granular inpatient pharmacy information	Resolved with partnerships with inpatient healthcare systems[10]
Inability to identify over-the-counter medication use	8	Over-the-counter medication use not captured	Inherent limitation of both claims and EHR data
Insufficient race capture of information on race	3	Race is not well-captured	FDA is working with Data Partners to understand approaches for better capture of this data
Insufficient representation of the population of interest	1	Limited generalizability based on commercial claims data	Sentinel added Medicare data in 2018 and Medicaid in 2022

ARIA, Active Risk Identification and Analysis; COVID, coronavirus disease; EHR, electronic health record; FDA, US Food and Drug Administration.

Slide courtesy of Rishi Desai

Sentinel Innovation Center Vision

Current Sentinel System Limitations

Inability to identify certain study populations of interest from insurance claims

Inability to identify certain outcomes of interest from insurance claims

Other limitations (inadequate duration of follow-up, the need for additional signal identification tools)

Sentinel Innovation Center Initiatives

Data Infrastructure

Feature Engineering

- Emerging methods including machine learning and scalable automated natural language processing (NLP) approaches to enable computable phenotyping from unstructured EHR data

Causal Inference

- Methodologic research to address specific challenges when using EHRs such as approaches to handle missing data, calibration methods for enhanced confounding adjustment

Detection Analytics

- Development of signal detection approaches to account for and leverage differences in data content and structure of EHRs

Sentinel Innovation Center Vision

A query-ready, quality-checked distributed data network containing EHR for at least 10 million lives with reusable analysis tools

2020 → 2024

Desai et al.npj Digital Medicine (2021) 4:170

Artificial Intelligence (AI) in Healthcare

Artificial Intelligence Timeline



Promise of Artificial Intelligence & Machine Learning



Ambient AI

https://capx.co/artificial-intelligence-could-be-the-radiologist-of-the-future/

Imaging Processing

Autonomous AI



In 2018, first Software as a Medical Device AI approved by FDA to not require physician interpretation.



Clinical Decision Support



Drug Discovery

CDS: Bleher H, Braun M, AI and Ethics, Jan 2022, DOI:10.1007/s43681-022-00135-x, autonomous AI: Abramoff MD, et al. Retina 10/2016. https://iovs.arvojournals.org/article.aspx?articleid=2565719

Gartner Hype Cycle for Artificial Intelligence

2019



2023



Numerous Potential Applications of Large Language Models (LLMs)

npj | digital medicine

PERSPECTIVE OPEN

Check for updates

The imperative for regulatory oversight of large language models (or generative AI) in healthcare

Bertalan Meskó[1,2]✉ and Eric J. Topol[3]



Timeline & Key Technologies for LLMs



Long Short-Term Memory (LSTM)



Word2Vec





Visual depiction of the CBOW deep learning model



https://www.analyticsvidhya.com/blog/2017/06/word-embeddings-count-word2veec/

https://arxiv.org/pdf/1301.3781.pdf

https://www.kdnuggets.com/2018/04/implementing-deep-learning-methods-feature-engineering-text-data-cbow.html

Transformer



https://arxiv.org/abs/1706.03762

Large Language Models

LLM Generation and Operation



Examples of LLMs

OpenAI Chat GPT-4

Bard

Meta AI

These are instances of what is known as **Generative AI**, which are a class of algorithms that can be used to create new content, including audio, code, images, text, simulations, and videos.

LLM Diversity & Growth of LLM Parameters



https://www.researchgate.net/publication/373642018_Large_language_models_in_medicine_the_potentials_and_pitfalls

Zero Shot & Few Shot Learning





https://saturncloud.io/blog/breaking-the-data-barrier-how-zero-shot-one-shot-and-few-shot-learning-are-transforming-machine-learning/

Retrieval Augmented Generation





https://www.promptingguide.ai/research/rag

Retrieval Augmented Generation



https://www.promptingguide.ai/research/rag

Recent LLM Iterations & Adaptations for Healthcare

Medical LLMs: Med-PaLM and Med-PaLM2 were trained and fine-tuned using various prompt tuning strategies on medical datasets. NYUTron and GatorTron, have also trained LLMs on EHR text data from healthcare systems



Fig. 1 Develop a clinical generative large language model, GatorTronGPT, for biomedical natural language processing, clinical text generation, and healthcare text evaluation. a Train GatorTronGPT from scratch using GPT-3 architecture with up to 20 billion parameters. **b** Solve biomedical relation extraction and question answering using a unified P-tuning base text generation architecture. **c** Apply GatorTronGPT to generate 20 billion words of synthetic clinical text, which was used to train synthetic natural language processing model, GatorTronS. **d** Turing evaluation of 30 paragraphs of text written by GatorTronGPT mixed with 30 real-world paragraphs written by UF Health physicians. TrM transformer unit; B billion.

https://www.nature.com/articles/s41746-023-00958-w

Opportunities & Challenges in the Use of Large Language Models in Medical Product Safety Surveillance

Importance of AI In Medical Product Safety

Executive Order October 30, 2023

… support … AI tools for … real-world evidence programs, population health, [and] public health

(e) To advance responsible AI innovation by a wide range of healthcare technology developers that promotes the welfare of patients and workers in the healthcare sector, the Secretary of HHS shall identify and, as appropriate and consistent with applicable law and the activities directed in section 8 of this order, prioritize grantmaking and other awards, as well as undertake related efforts, to support responsible AI development and use, including:

(i) collaborating with appropriate private sector actors through HHS programs that may support the advancement of AI-enabled tools that develop personalized immune-response profiles for patients, consistent with section 4 of this order;

(ii) prioritizing the allocation of 2024 Leading Edge Acceleration Project cooperative agreement awards to initiatives that explore ways to improve healthcare-data quality to support the responsible development of AI tools for clinical care, real-world-evidence programs, population health, public health, and related research; and

https://www.whitehouse.gov/briefing-room/presidential-actions/2023/10/30/executive-order-on-the-safe-secure-and-trustworthy-development-and-use-of-artificial-intelligence/

Opportunities for LLMs in Post-Market Surveillance



Important Data Sources for Post-Market Surveillance

Medical Claims

Electronic Health Records (EHR)

U.S. FOOD & DRUG
ADMINISTRATION

Adverse Event Reporting System

Publicly Available Content on the Internet

Vital Statistics



Adverse Event (AE) Detection

RESEARCH ARTICLE PLOS ONE

AE-GPT: Using Large Language Models to extract adverse events from surveillance reports-A use case with influenza vaccine adverse events

Yiming Li[1], Jianfu Li[2], Jianping He[1], Cui Tao[2]*



Prompt

```
"question": "Please extract all the names of nervous_AE from
the following note",
```

Annotations

```
      "answers":
            "text": "Guillain Barre Syndrome",
            "answer_start": 0
            "text": "quadriplegic",
            "answer_start": 141
            "text": "GBS",
            "answer_start": 212
```

Prompt

```
"context": "Guillain Barre Syndrome. Onset on symptoms
1/23/05. Increased CSF protein. Progressed to respiratory
failure - BIPAP 1/31. Currently in ICU; quadriplegic.
4/25/05 Progress note from Neuro states confirmation of GBS
based on unfinished EMG report. "
```

Prompt

```
   "prompt": "Guillain Barre Syndrome. Onset on symptoms
1/23/05. Increased CSF protein. Progressed to respiratory
failure - BIPAP 1/31. Currently in ICU; quadriplegic.  4/25/05
Progress note from Neuro states confirmation of GBS based on
unfinished EMG report.  ###  "
```

Annotations

```
   "completion":
      "nervous_AE:['Guillain Barre Syndrome',
                 'quadriplegic', 'GBS']
      timestamp:['1/23/05', '1/31']
      investigation:['Increased CSF protein', 'EMG']
      other_AE:['respiratory failure']
      procedure:['BIPAP', 'ICU']
      END"
```

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0300919

Probabilistic Computable Phenotyping

What do we mean by probabilistic computable phenotyping?

- An attempt to accurately identify a health condition of interest from healthcare data using combination of various sources of information eg diagnosis codes, procedures, medications, symptoms in physician notes (aka “features”)
- For many conditions, complex algorithms are needed to integrate various sources of information to assign probabilities of having the condition of interest in a patient given her profile
- When these algorithms are created, we typically need to validate our predictions against some “gold-standard” truth to determine the best approach

Slide courtesy of Rishi Desai

medRxiv
THE PREPRINT SERVER FOR HEALTH SCIENCES

Follow this preprint

Scalable Incident Detection via Natural Language Processing and Probabilistic Language Models

Colin G. Walsh, Drew Wilimitis, Qingxia Chen, Aileen Wright, Jhansi Kolli, Katelyn Robinson, Michael A. Ripperger, Kevin B. Johnson, David Carrell, Rishi J. Desai, Andrew Mosholder, Sai Dharmarajan, Sruthi Adimadhyam, Daniel Fabbri, Danijela Stojanovic, Michael E. Matheny, Cosmin A. Bejan

doi: https://doi.org/10.1101/2023.11.30.23299249

Journal of the American Medical Informatics Association, 2023, 1–9
https://doi.org/10.1093/jamia/ocad241
Research and Applications

AMIA INFORMATICS PROFESSIONALS. LEADING THE WAY.
OXFORD

Research and Applications

Data-driven automated classification algorithms for acute health conditions: applying PheNorm to COVID-19 disease

Joshua C. Smith, PhD[1,*], Brian D. Williamson, PhD[2], David J. Cronkite, MS[2], Daniel Park, BS[1], Jill M. Whitaker, MSN[1], Michael F. McLemore, BSN[1], Joshua T. Osmanski, MS[1], Robert Winter, BA[1], Arvind Ramaprasan, MS[2], Ann Kelley, MHA[2], Mary Shea, MA[2], Saranrat Wittayanukorn, PhD[3], Danijela Stojanovic, PharmD, PhD[3], Yueqin Zhao, PhD[3], Sengwee Toh, ScD[4], Kevin B. Johnson, MD, MS[5], David M. Aronoff, MD[6], David S. Carrell, PhD[2]

[1]Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN 37203, United States, [2]Kaiser Permanente Washington Health Research Institute, Seattle, WA 98101, United States, [3]Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20903, United States, [4]Harvard Pilgrim Health Care Institute, Boston, MA 02215, United States, [5]Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA 19104, United States, [6]Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, United States

*Corresponding author: Joshua C. Smith, PhD, Department of Biomedical Informatics, Vanderbilt University Medical Center, 2525 West End Avenue, Suite No. 1400, Nashville, TN 37203 (joshua.smith@vumc.org)

AJE
American Journal of Epidemiology
Vol. 192, No. 2
https://doi.org/10.1093/aje/kwac182
Advance Access publication: November 4, 2022

Practice of Epidemiology

Improving Methods of Identifying Anaphylaxis for Medical Product Safety Surveillance Using Natural Language Processing and Machine Learning

David S. Carrell*, Susan Gruber, James S. Floyd, Maralyssa A. Bann, Kara L. Cushing-Haugen, Ron L. Johnson, Vina Graham, David J. Cronkite, Brian L. Hazlehurst, Andrew H. Felcher, Cosmin A. Bejan, Adee Kennedy, Mayura U. Shinde, Sara Karami, Yong Ma, Danijela Stojanovic, Yueqin Zhao, Robert Ball, and Jennifer C. Nelson

* Correspondence to Dr. David Carrell, Kaiser Permanente Washington Health Research Institute, 1730 Minor Avenue, Suite 1600, Seattle, WA 98101 (e-mail: david.s.carrell@kp.org).

Initially submitted August 11, 2021; accepted for publication October 11, 2022.

High Throughput Phenotyping



Zhang et al. *Nat protocols*. 2019

VANDERBILT UNIVERSITY MEDICAL CENTER

LLMs Facilitate Generation of EHR Phenotyping Algorithms



Figure 1. An architectural overview of the study pipeline.



Figure 2. A comparative analysis based on expert evaluations focusing on A) four large language models, B) two prompting strategies, C) three phenotypes, and D) three individual evaluation axes. Numeric scores of 3, 2, and 1 correspond to expert assessments of "Good", "Medium", and "Poor", respectively. ***, **, and * denote $p<0.001$, $p<0.01$, and $p<0.05$, respectively. ns=not significant.

Table 2. Performance of the phenotyping algorithms generated by GPT-4 and GPT-3.5 from the β-prompting strategy when applied to VUMC data, as measured against clinician-validated algorithms for the eMERGE phenotype cases and controls.

Disease	eMERGE		GPT-4					GPT-3.5				
	True cases	True controls	TP	FP	PPV	Recall	FPR	TP	FP	PPV	Recall	FPR
T2DM	9,293	23,754	8,978	578	53.3%	96.6%	2.4%	0	0	-	0.0%	0.0%
Dementia	2,985	77,575	729	11	96.3%	24.4%	0.01%	2,388	583	71.4%	80.0%	7.5%
Hypo-thyroidism	2,030	25,760	2,029	258	9.6%	99.9%	1.0%	2,029	1,065	10.7%	99.9%	4.1%

TP=true positive; FP=false positive; FDR=false discovery rate; T2DM=type 2 diabetes mellitus.

https://pubmed.ncbi.nlm.nih.gov/38196578/ MedRxIV not Peer Reviewed, Yan, Chao, et al, Wei, Wei-QI

LLM Clinical Text Summarization



c

Input: there is no appreciable change in the small right subarachnoid hemorrhage compared to the prior examination. there is no evidence of a compressive lesion or shift of normally midline structures. there is no acute infarction within a major vascular territory. there is periventricular and subcortical hypodensities, likely the sequelae of chronic small vessel disease with focal hypodensity within the subcortical white matter subjacent to the precentral gyrus, that might represent chronic infarction. the ventricles and sulci are normal in size and configuration. there is no acute bony abnormality. the visualized paranasal sinuses and mastoid air cells are well aerated.

Summary A: 1. stable small right subarachnoid hemorrhage. 2. no acute intracranial process. 3. chronic small vessel ischemic disease.

Summary B: no interval change in small right subarachnoid hemorrhage, without evidence of new hemorrhage, compressive lesion or shift of normally midline structures.

Which summary...

	A: significantly	A: slightly	neither	B: slightly	B: significantly
... more completely captures important information?	○	○	○	○	○
... includes less false information?	○	○	○	○	○
... contains less non-important information?	○	○	○	○	○

[Clinical Text Summarization: Adapting Large Language Models Can Outperform Human Experts | Research Square]

But What About the Challenges?

Careful Prompt Engineering – A New (Complex) Domain



Figure 2: Taxonomy of prompt engineering techniques in LLMs, organized around application domains, providing a nuanced framework for customizing prompts across diverse contexts.

https://arxiv.org/abs/2402.07927

In General LLM Use:

Large and growing array of techniques and considerations for prompt engineering:

- New Tasks Without Extensive Training
- For Reasoning and Logic
- To Reduce Hallucinations
- Knowledge-Based Reasoning and Generation
- Understanding User Intent

and many more…

In Medical Product Surveillance:

Important to carefully generate prompts to ensure that the LLM extracted relationships are:

- temporally accurate (i.e., exposure before adverse event)
- focus on eliciting highly specific responses since ambiguity in clinical text is common
  - (e.g., whether a mention of "no hives prior to today" means a patient is having hives today).

Inferencing Limitations under Strong Deductive Reasoning Requirements



Figure 1: Breakdown of the different types of problems we examine.

Instruction sentence: *Pick two cards that are required to determine if the rule is true:*
Sample Context Sentence: *An attendant needs to make sure that customers are following the rules.*
Familiar Social Rule: *The rule is that if the customer is over 25 they can drive a rental car.*
Unfamiliar Social Rule: *The rule is that if the customer is over 25 they must be in elementary school.*
Familiar Non-social Rule: *The rule is that if the equipment is a laptop then it must have a plastic keyboard.*
Unfamiliar Non-social Rule: *The rule is that if the equipment is a laptop then it must have a grass keyboard.*
Shuffled Unfamiliar Non-social Rule: *The rule is that if the equipment has a grass keyboard then it must be a laptop.*
Arbitrary: *The rule is that if the cards have a type of food then they must have an outdoor activity.*

Table 2: Example Problems



Figure 7: Evaluation of whether the LLMs select an antecedent card. Content type: **arbitrary** (AR), **shuffled** (SH), and **familiar** (FM). Presentation formats: **classic**, **front**, **back**, and **both**. Social rule status: **non-social rule**, **social rule**. Collapsed over LLM.

https://arxiv.org/abs/2309.05452

Challenges Regarding Patient Protected Health Information

Limitations in use of cloud computing and API-based solutions (Chat-GPT, BARD) because of uploading data, requires enclosures & agreements between vendors and healthcare data owners



Fig. 1: An illustration of PII extraction, reconstruction and inference attack techniques.



Fig. 2: Utilities of LMs trained (i) undefended, (ii) with scrubbing, (iii) with DP ($\varepsilon = 8$), (iv) with scrubbing + DP, and (v) with masked outputs in an ablation study over the LM's size on the ECHR dataset (see Section IV for details).

2302.00539.pdf (arxiv.org)

Even with Differential Privacy, Masking, and PII Removal from training sets, risk of PII leakage under adversarial attack of LLM – requires careful consideration of release of any LLM trained with medical data

LLM Hallucinations : Clinical Example

Question

A 24-year-old pregnant woman at 28 weeks gestation presents to the emergency department with complaints of fever with chills and pain in her knee and ankle joints for the past 2 days. she also complains of headaches and difficulty moving her neck. further questioning reveals that she had a tick bite on her arm while gardening a few days ago.pregnancy is progressing normally. on examination, an erythematous rash is seen on her right arm. her obstetric examination is normal. ultrasound of the fetus is reassuring with a normal heartbeat and no gross abnormalities. a specimen is collected to test for lyme disease. what is the next best step for this patient?

Options

A) Ibuprofen

B) Tetracycline

C) Amoxicilin

D) Gentamicin

2307.15343.pdf (arxiv.org)

LLM Hallucinations : Clinical Example

Physician

Amoxicillin

Explanation : amoxicillin is a safe and effective treatment for lyme disease in pregnancy. ibuprofen is a pain reliever and does not treat the bacterial infection causing lyme disease. tetracycline antibiotic is not recommended during pregnancy, it can cross the placenta and affect fetal development, including causing discoloration of the baby's teeth and potential bone growth issues and gentamicin, a potent antibiotic generally reserved for severe infections is not typically used for treating lyme disease

GPT-3.5

Tetracycline X

Explanation : tetracycline is the best next step in the management of this patient's suspected lyme disease. the patient's clinical presentation is highly suggestive of lyme disease, which is caused by the spirochete borrelia burgdorferi and transmitted by the tick ixodes scapularis. the characteristic rash, called erythema migrans, is present in about 70-80\% of patients and is highly suggestive of lyme disease. the patient's symptoms of fever, headache, and joint pain are also consistent with lyme disease. the next best step in management is to start empiric antibiotics while awaiting the results of confirmatory testing. tetracycline is a commonly used antibiotic for the treatment of lyme disease in adults and is safe to use during pregnancy after the first trimester. it has been shown to be effective in eradicating b. burgdorferi and preventing the progression of lyme disease. ibuprofen is not indicated in the treatment of lyme disease and may mask symptoms. ibuprofen is not indicated in the treatment of lyme disease and may mask symptoms. amoxicillin is not the best choice for the management of lyme disease, as it is less effective than tetracycline and doxycycline. gentamicin is not an effective treatment for lyme disease

2307.15343.pdf (arxiv.org)

Continuous Learning and Changes in Performance Over Time



Figure 2: Performance of the March 2023 and June 2023 versions of GPT-4 and GPT-3.5 on eight tasks:

Continual evolution of LLMs create variation in accuracy.

Performance on 8 key prompts changes over time in 2023, some improving and some worsening.

Chen L, Zaharia M, Zou J. arXiv. https://doi.org/10.48550/arXiv.2307.09009

We Have a Long Way To Go!

Literature Review of Current LLM Evaluations

	Accuracy	Comprehensiveness	Factuality	Robustness	Interpretive Evaluation	Deployment Metrics	Calibration and Uncertainty	TOTAL NUMBER OF PAPERS Number	%
Medical Education	408	183	104	98	26	24	8	231	44.5%
Diagnostics	180	66	28	23	33	12	0	101	19.5%
Patient education	192	157	91	56	32	8	6	92	17.7%
Patient care delivery	75	44	22	23	5	2	0	48	9.2%
Patient communication	56	45	20	27	29	2	0	39	7.5%
Care coordination and planning	45	28	8	6	8	1	0	39	7.5%
Clinical Triage	46	14	15	5	20	20	0	24	4.6%
Literature review	38	13	6	13	3	11	0	18	3.5%
Data synthesis	25	19	6	5	2	5	0	17	3.3%
Clinical Referrals	4	0	0	0	0	2	0	3	0.6%
Medical report-generation	14	12	3	0	4	0	0	9	1.7%
Clinical knowledge management	12	8	2	2	0	0	0	6	1.2%
Patient panel management	21	15	9	9	3	2	0	8	1.5%
Clinical note-taking	6	2	2	1	0	0	1	4	0.8%
Surgery Assistance	6	6	2	2	0	0	0	3	0.6%
Medical research	20	18	11	7	5	3	0	9	1.7%
Clinical trials	13	0	0	13	3	13	0	2	0.4%
Patient monitoring	3	1	0	2	2	0	0	2	0.4%
Billing	1	0	0	0	0	0	0	1	0.2%
Prescriptions	1	0	0	0	0	0	0	1	0.2%
Question Answering	490	232	90	73	64	18	7	437	84.2%
Text Classification	141	77	49	42	26	14	4	145	27.9%
Information Extraction	126	77	51	37	20	14	3	128	24.7%
Summarization	51	36	17	9	8	1	1	46	8.9%
Translation	15	8	6	4	3	2	0	16	3.1%
Conversational Dialogue	13	9	4	4	7	1	0	17	3.3%
TOTAL NUMBER OF PAPERS	495	244	95	77	82	24	6		
%	95.4%	47.0%	18.3%	14.8%	15.8%	4.6%	1.2%		

Personal Communication Nigam Shah (in submission)

Conclusions

- LLMs are an amazing new technology with rapid growth and evolution of capacity and reach
- Key Opportunities in Medical Product Safety Surveillance
  - Adverse Event Detection
  - Probabilistic Phenotyping
  - Information Synthesis
- Key Challenges In Safe & Effective Use
  - Lack of Evaluation for Medical Product Surveillance
  - Complexities of Prompt Engineering
  - Hallucination Risk (False Positives)
  - Evolving Models over Time Challenge Stable Performance Estimates

Sentinel

Thank You

Michael Matheny

For more information contact:

michael.matheny@va.gov

michael.matheny@vumc.org

@MichaelEMatheny

VANDERBILT UNIVERSITY MEDICAL CENTER

iPHI Center for Improving the Public's Health through Informatics

DEPARTMENT OF VETERANS AFFAIRS UNITED STATES OF AMERICA